Oxford Cardiomox

Curated by Signal

Developer of device for early diagnosis of heart disease

Overview

Oxford Cardiomox is developing the device for early diagnosis of heart disease. The company has developed the device called cardiomox-MCG9 in conjugation with AI supported diagnostic tools. The device provides non invasive solution to diagnose cardiac diseases such as myocardial ischemia and arrhythmia. The company has patent for the detection of myocardium damage, biomagnetic measurement, and screening of touch sensitive magnetocardiograph unit among others.

Key facts

Founded: 2013
Headquarters: Oxford, United Kingdom
Stage: Sign up to view
Industry: Life Sciences Technology

Contact

Email: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

Genome Carver
Provider of software platform for synthetic genomics
Life Sciences TechnologyEdinburgh, United Kingdom
baseimmune
Developer of AI based vaccines for treating infectious diseases
Life Sciences TechnologyLondon, United Kingdom
PostEra
AI based molecular designing software for drug discovery
Life Sciences TechnologyLondon, United Kingdom

About Oxford Cardiomox

What does Oxford Cardiomox do?

Oxford Cardiomox is developing the device for early diagnosis of heart disease.

Where is Oxford Cardiomox headquartered?

Oxford Cardiomox is headquartered in Oxford, United Kingdom.

When was Oxford Cardiomox founded?

Oxford Cardiomox was founded in 2013.

Which sector is Oxford Cardiomox in?

Oxford Cardiomox operates in Life Sciences Technology.

Who are Oxford Cardiomox's competitors?

Companies similar to Oxford Cardiomox include Genome Carver, baseimmune, and PostEra.